ADBICA: Difference between revisions
Added section describing data on adverse effects reported to the New Zealand government. |
m typo |
||
| Line 41: | Line 41: | ||
==Adverse Effects== |
==Adverse Effects== |
||
[[Designer drug]]'s that include ADBICA as their primary psychoactive ingredient were approved for sale in New Zealand in 2013.<ref>{{cite web|last=New Zealand Government Ministry of Health|title=Synthetic cannabinoids – Approved or rejected applications 27 Sept 2013|url=http://www.health.govt.nz/system/files/documents/pages/risk-assessment-score-table-27sept-13.pdf|accessdate=8 January 2014}}</ref> As of September 2013, three, non-specified, minor adverse effects had been reported in products containing |
[[Designer drug]]'s that include ADBICA as their primary psychoactive ingredient were approved for sale in New Zealand in 2013.<ref>{{cite web|last=New Zealand Government Ministry of Health|title=Synthetic cannabinoids – Approved or rejected applications 27 Sept 2013|url=http://www.health.govt.nz/system/files/documents/pages/risk-assessment-score-table-27sept-13.pdf|accessdate=8 January 2014}}</ref> As of September 2013, three, non-specified, minor adverse effects had been reported in products containing ADBICA. <ref>{{cite web|last=New Zealand Government Ministry of Health|title=Synthetic cannabinoids – Approved or rejected applications 27 Sept 2013|url=http://www.health.govt.nz/system/files/documents/pages/risk-assessment-score-table-27sept-13.pdf|accessdate=8 January 2014}}</ref> |
||
Revision as of 09:01, 8 January 2014
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| ChemSpider | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H29N3O2 |
| Molar mass | 343.46 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADBICA is a designer drug identified in synthetic cannabis blends in Japan in 2013.[1] ADBICA is unprecedented in the scientific literature.[clarification needed] ADBICA features a carboxamide group at the 3-indole position, like SDB-001 and STS-135. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved, though in a large series of indazole derivatives structurally similar to ADBICA that are disclosed in Pfizer patent WO 2009/106980, activity resides exclusively in the (S) enantiomers.[2] Nothing is known of the pharmacological activity of ADBICA in humans or other animals.
Adverse Effects
Designer drug's that include ADBICA as their primary psychoactive ingredient were approved for sale in New Zealand in 2013.[3] As of September 2013, three, non-specified, minor adverse effects had been reported in products containing ADBICA. [4]
See also
References
- ^ Template:Cite DOI
- ^ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106980
- ^ New Zealand Government Ministry of Health. "Synthetic cannabinoids – Approved or rejected applications 27 Sept 2013" (PDF). Retrieved 8 January 2014.
- ^ New Zealand Government Ministry of Health. "Synthetic cannabinoids – Approved or rejected applications 27 Sept 2013" (PDF). Retrieved 8 January 2014.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |